Are Analysts Bullish about Veracyte, Inc. (NASDAQ:VCYT) after last week?

March 20, 2018 - By Richard Conner

 Are Analysts Bullish about Veracyte, Inc. (NASDAQ:VCYT) after last week?
Investors sentiment decreased to 1.76 in 2017 Q3. Its down 0.12, from 1.88 in 2017Q2. It worsened, as 11 investors sold Veracyte, Inc. shares while 14 reduced holdings. 14 funds opened positions while 30 raised stakes. 22.46 million shares or 6.26% more from 21.14 million shares in 2017Q2 were reported.
Jpmorgan Chase & reported 18,905 shares. Prelude Cap Mngmt Lc accumulated 21,800 shares or 0.02% of the stock. Meeder Asset has 1,240 shares for 0% of their portfolio. State Of Wisconsin Inv Board invested 0% of its portfolio in Veracyte, Inc. (NASDAQ:VCYT). Bridgeway Capital Mgmt Inc stated it has 356,800 shares or 0.04% of all its holdings. Royal Bank Of Canada invested in 12,937 shares or 0% of the stock. Spark Inv Mngmt Ltd Company stated it has 78,374 shares. Renaissance Technology Limited Liability Com holds 0.01% of its portfolio in Veracyte, Inc. (NASDAQ:VCYT) for 554,759 shares. The California-based Board Of Trustees Of The Leland Stanford Junior University has invested 0.01% in Veracyte, Inc. (NASDAQ:VCYT). Essex Invest Management Com Limited Liability Com stated it has 0.22% in Veracyte, Inc. (NASDAQ:VCYT). California State Teachers Retirement accumulated 37,021 shares. Broadfin Lc owns 1.02 million shares. Tower Rech Cap Limited Liability Co (Trc) holds 0% or 3,535 shares in its portfolio. Susquehanna Interest Grp Limited Liability Partnership holds 0% of its portfolio in Veracyte, Inc. (NASDAQ:VCYT) for 39,293 shares. Boston Advisors Ltd holds 58,910 shares.

Since September 25, 2017, it had 0 insider buys, and 3 insider sales for $381,180 activity. 20,000 shares valued at $180,000 were sold by Hall Christopher M on Monday, October 2.

Veracyte, Inc. (NASDAQ:VCYT) Ratings Coverage

Among 6 analysts covering Veracyte (NASDAQ:VCYT), 4 have Buy rating, 0 Sell and 2 Hold. Therefore 67% are positive. Veracyte had 11 analyst reports since August 14, 2015 according to SRatingsIntel. BTIG Research maintained the stock with “Buy” rating in Friday, August 14 report. The firm has “Neutral” rating by Janney Capital given on Tuesday, November 7. The firm has “Overweight” rating given on Friday, August 14 by Piper Jaffray. The rating was downgraded by Piper Jaffray on Tuesday, November 7 to “Hold”. The stock of Veracyte, Inc. (NASDAQ:VCYT) has “Buy” rating given on Friday, December 18 by Cantor Fitzgerald. The firm has “Outperform” rating by Leerink Swann given on Tuesday, November 7. The stock has “Buy” rating by Janney Capital on Tuesday, November 29. Below is a list of Veracyte, Inc. (NASDAQ:VCYT) latest ratings and price target changes.

07/11/2017 Broker: Piper Jaffray Rating: Hold Downgrade
07/11/2017 Broker: Leerink Swann Rating: Outperform Old Target: $12 New Target: $9 Maintain
07/11/2017 Broker: Janney Capital Old Rating: Buy New Rating: Neutral Downgrade
26/09/2017 Broker: Janney Capital Rating: Buy

The stock decreased 0.48% or $0.03 during the last trading session, reaching $6.16. About 79,658 shares traded. Veracyte, Inc. (NASDAQ:VCYT) has risen 56.46% since March 20, 2017 and is uptrending. It has outperformed by 39.76% the S&P500.

Veracyte, Inc. operates as a molecular diagnostics firm in the United States. The company has market cap of $211.23 million. The firm uses genomic technology to resolve diagnostic ambiguity. It currently has negative earnings. It offers Afirma Thyroid FNA Analysis solution for use in thyroid cancer diagnosis; cytopathology testing services; and the Afirma Malignancy Classifiers to manage thyroid nodule patients.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.